Based on this peculiar effect, ET-743 was evaluated in patients with advanced non-small-cell lung cancer (NSCLC) after platinum treatment where XPG is over-expressed [73] or with patients with advanced ovarian cancer where XPG is mutated [74]. This evidence concerns the gene ERCC5 and ovarian cancer.